Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study

Inclusion Criteria: * Female patients ≥ 18 years old with histologically confirmed Stage III or IV epithelial ovarian, primary peritoneal, or fallopian tube cancer who were enrolled in CAN-003 * Able and willing to undergo mononuclear cell (MNC) collection (if required for patients who do not have available Cvac doses) * Were enrolled in CAN-003 and met protocol criteria for progressive disease * Wish to remain in the study and, in the investigator's judgment, the potential benefit of Cvac treatment outweighs the risk * Must be non-pregnant and, if of childbearing potential, must use adequate birth control (hormonal or barrier method of birth control or abstinence) for the duration of the study and for 3 months after study completion * Able to provide written informed consent * White blood cell count (WBC) ≥ 3.0 K/μL, absolute neutrophil count ≥ 1.5 K/μL, hemoglobin ≥ 9.0 g/dL, and platelets ≥100,000/mm\^3 Exclusion Criteria: * Pregnant or breastfeeding * Other medical conditions which preclude study participation, in the opinion of the investigator * Receiving treatment with any other investigational product